Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
J Med Chem
2020 Aug 13;6315:8380-8387. doi: 10.1021/acs.jmedchem.0c00613.
Show Gene links
Show Anatomy links
Development of Conformationally Constrained α-RgIA Analogues as Stable Peptide Antagonists of Human α9α10 Nicotinic Acetylcholine Receptors.
Zheng N
,
Christensen SB
,
Blakely A
,
Dowell C
,
Purushottam L
,
McIntosh JM
,
Chou DH
.
???displayArticle.abstract???
Non-opioid therapeutics for the treatment of neuropathic pain are urgently needed to address the ongoing opioid crisis. Peptides from cone snail venoms have served as invaluable molecules to target key pain-related receptors but can suffer from unfavorable physicochemical properties, which limit their therapeutic potential. In this work, we developed conformationally constrained α-RgIA analogues with high potency, receptor selectivity, and enhanced human serum stability to target the human α9α10 nicotinic acetylcholine receptor. The key lactam linkage introduced in α-RgIA fixed the favored globular conformation and suppressed disulfide scrambling. The NMR structure of the macrocyclic peptide overlays well with that of α-RgIA4, demonstrating that the cyclization does not perturb the overall conformation of backbone and key side-chain residues. Finally, a molecular docking model was used to rationalize the selective binding between a macrocyclic analogue and the α9α10 nicotinic acetylcholine receptor. These conformationally constrained antagonists are therefore promising candidates for antinociceptive therapeutic intervention.
???displayArticle.pubmedLink???
32597184
???displayArticle.pmcLink???PMC7942019 ???displayArticle.link???J Med Chem ???displayArticle.grants???[+]
Akondi,
Discovery, synthesis, and structure-activity relationships of conotoxins.
2014, Pubmed
Akondi,
Discovery, synthesis, and structure-activity relationships of conotoxins.
2014,
Pubmed
Alonso,
Drugs from the sea: conotoxins as drug leads for neuropathic pain and other neurological conditions.
2003,
Pubmed
Azam,
Molecular basis for the differential sensitivity of rat and human α9α10 nAChRs to α-conotoxin RgIA.
2012,
Pubmed
,
Xenbase
Azam,
Molecular interaction of α-conotoxin RgIA with the rat α9α10 nicotinic acetylcholine receptor.
2015,
Pubmed
Brady,
Prescription Opioid Misuse, Abuse, and Treatment in the United States: An Update.
2016,
Pubmed
Bulaj,
Folding of conotoxins: formation of the native disulfide bridges during chemical synthesis and biosynthesis of Conus peptides.
2008,
Pubmed
Burke,
Forecasting the opioid epidemic.
2016,
Pubmed
Chhabra,
Dicarba analogues of α-conotoxin RgIA. Structure, stability, and activity at potential pain targets.
2014,
Pubmed
Christensen,
RgIA4 Potently Blocks Mouse α9α10 nAChRs and Provides Long Lasting Protection against Oxaliplatin-Induced Cold Allodynia.
2017,
Pubmed
,
Xenbase
Clark,
The engineering of an orally active conotoxin for the treatment of neuropathic pain.
2010,
Pubmed
Clark,
Engineering stable peptide toxins by means of backbone cyclization: stabilization of the alpha-conotoxin MII.
2005,
Pubmed
,
Xenbase
Dekan,
α-Conotoxin ImI incorporating stable cystathionine bridges maintains full potency and identical three-dimensional structure.
2011,
Pubmed
Dougherty,
Enhancing the Cell Permeability of Stapled Peptides with a Cyclic Cell-Penetrating Peptide.
2019,
Pubmed
Ellison,
Alpha-RgIA, a novel conotoxin that blocks the alpha9alpha10 nAChR: structure and identification of key receptor-binding residues.
2008,
Pubmed
Ellison,
Alpha-RgIA: a novel conotoxin that specifically and potently blocks the alpha9alpha10 nAChR.
2006,
Pubmed
,
Xenbase
Gori,
Stabilization of the cysteine-rich conotoxin MrIA by using a 1,2,3-triazole as a disulfide bond mimetic.
2015,
Pubmed
Gori,
Disulfide Bond Mimetics: Strategies and Challenges.
2017,
Pubmed
Halai,
Effects of cyclization on stability, structure, and activity of α-conotoxin RgIA at the α9α10 nicotinic acetylcholine receptor and GABA(B) receptor.
2011,
Pubmed
,
Xenbase
Hoang,
Short Hydrophobic Peptides with Cyclic Constraints Are Potent Glucagon-like Peptide-1 Receptor (GLP-1R) Agonists.
2015,
Pubmed
Hone,
α9-containing nicotinic acetylcholine receptors and the modulation of pain.
2018,
Pubmed
Hosseini,
Non-additive stabilization by halogenated amino acids reveals protein plasticity on a sub-angstrom scale.
2017,
Pubmed
Jin,
Conotoxins: Chemistry and Biology.
2019,
Pubmed
Khoo,
Lactam-stabilized helical analogues of the analgesic μ-conotoxin KIIIA.
2011,
Pubmed
,
Xenbase
Li,
Interaction of rat α9α10 nicotinic acetylcholine receptor with α-conotoxin RgIA and Vc1.1: Insights from docking, molecular dynamics and binding free energy contributions.
2019,
Pubmed
Livett,
Therapeutic applications of conotoxins that target the neuronal nicotinic acetylcholine receptor.
2006,
Pubmed
MacRaild,
Structure and activity of (2,8)-dicarba-(3,12)-cystino alpha-ImI, an alpha-conotoxin containing a nonreducible cystine analogue.
2009,
Pubmed
McIntosh,
Alpha9 nicotinic acetylcholine receptors and the treatment of pain.
2009,
Pubmed
,
Xenbase
Miranda,
Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo activity.
2008,
Pubmed
Mohammadi,
Conotoxin Interactions with α9α10-nAChRs: Is the α9α10-Nicotinic Acetylcholine Receptor an Important Therapeutic Target for Pain Management?
2015,
Pubmed
Moroder,
Synthesis of single- and multiple-stranded cystine-rich peptides.
2005,
Pubmed
Murage,
Development of potent glucagon-like peptide-1 agonists with high enzyme stability via introduction of multiple lactam bridges.
2010,
Pubmed
Murnion,
Neuropathic pain: current definition and review of drug treatment.
2018,
Pubmed
Muttenthaler,
Solving the alpha-conotoxin folding problem: efficient selenium-directed on-resin generation of more potent and stable nicotinic acetylcholine receptor antagonists.
2010,
Pubmed
,
Xenbase
Netirojjanakul,
Progress and challenges in the optimization of toxin peptides for development as pain therapeutics.
2017,
Pubmed
Pennington,
Peptide therapeutics from venom: Current status and potential.
2018,
Pubmed
Qu,
Synthesis of Disulfide Surrogate Peptides Incorporating Large-Span Surrogate Bridges Through a Native-Chemical-Ligation-Assisted Diaminodiacid Strategy.
2020,
Pubmed
Romero,
Inhibition of α9α10 nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic pain.
2017,
Pubmed
Sadeghi,
Structure-Activity Studies Reveal the Molecular Basis for GABAB-Receptor Mediated Inhibition of High Voltage-Activated Calcium Channels by α-Conotoxin Vc1.1.
2018,
Pubmed
,
Xenbase
Safavi-Hemami,
Pain therapeutics from cone snail venoms: From Ziconotide to novel non-opioid pathways.
2019,
Pubmed
Sanford,
Intrathecal ziconotide: a review of its use in patients with chronic pain refractory to other systemic or intrathecal analgesics.
2013,
Pubmed
Shinada,
Halogens in Protein-Ligand Binding Mechanism: A Structural Perspective.
2019,
Pubmed
Wang,
Designing macrocyclic disulfide-rich peptides for biotechnological applications.
2018,
Pubmed
Yang,
Stabilized β-Hairpin Peptide Inhibits Insulin Degrading Enzyme.
2018,
Pubmed
Yu,
Molecular Determinants Conferring the Stoichiometric-Dependent Activity of α-Conotoxins at the Human α9α10 Nicotinic Acetylcholine Receptor Subtype.
2018,
Pubmed
,
Xenbase
Zouridakis,
Crystal Structure of the Monomeric Extracellular Domain of α9 Nicotinic Receptor Subunit in Complex With α-Conotoxin RgIA: Molecular Dynamics Insights Into RgIA Binding to α9α10 Nicotinic Receptors.
2019,
Pubmed
de Araujo,
Total synthesis of the analgesic conotoxin MrVIB through selenocysteine-assisted folding.
2011,
Pubmed
,
Xenbase
de Araujo,
Selenoether oxytocin analogues have analgesic properties in a mouse model of chronic abdominal pain.
2014,
Pubmed
